Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
-
TCRs for an HLA-A*02:01 epitope of PRAME now in IND-enabling studies Multiplexing TCRs for MAGE-A1 and PRAME demonstrates synergistic cytotoxicity in vitro and in mouse xenograft models Company...
-
Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET...
-
Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors Monday, November 14th at 5:00 PM ET WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc....
-
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
-
WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
-
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
-
Financing supports management’s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, Mass., Sept. 12,...
-
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
-
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs ...